Standout Papers
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials (2012)
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study (2011)
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status (2011)
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial (2013)
Immediate Impact
1 by Nobel laureates 16 from Science/Nature 72 standout
Citing Papers
Cancer Statistics, 2021
2021 Standout
Evaluating eligibility criteria of oncology trials using real-world data and AI
2021 StandoutNature
Works of Ilhan Celik being referenced
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ilhan Celik | 1615 | 2782 | 668 | 886 | 30 | 3.8k | |
| J. Załuski | 1659 | 3637 | 803 | 910 | 22 | 4.4k | |
| Michelle R. Mahoney | 1667 | 3301 | 1131 | 1305 | 71 | 4.7k | |
| Francesca Molinari | 1508 | 3036 | 449 | 1441 | 52 | 4.6k | |
| Johannes Nippgen | 1415 | 3151 | 651 | 905 | 27 | 4.2k | |
| Jan Stoehlmacher | 1762 | 3374 | 1117 | 965 | 57 | 5.2k | |
| Frank Cihon | 1534 | 2468 | 319 | 660 | 32 | 3.7k | |
| A. Roth | 1312 | 2722 | 1018 | 754 | 55 | 3.9k | |
| Piercarlo Saletti | 2040 | 4167 | 919 | 1565 | 74 | 5.4k | |
| Jean–Luc Van Laethem | 1423 | 3038 | 798 | 617 | 47 | 3.7k | |
| J. Randolph Hecht | 1826 | 2728 | 699 | 610 | 78 | 4.1k |
All Works
Loading papers...